E
Onconetix, Inc. ONCO
$0.0761 -$0.0039-4.88% NASDAQ
Recommendation
Prev Close
$0.08
Volume
26,597,265
Avg Vol (90D)
11,121,245
Market Cap
$663.58K
Dividend & Yield
--
52-Week Range
$0.0502 - $21.40
P/E (TTM)
--
EPS (TTM)
-$95.63
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Onconetix faces third delisting threat since 2022 IPO
4/21/2025 - Bizjournals.com - Health Care News
Cincinnati's Onconetix pursuing merger deal with drug development firm
4/8/2025 - Bizjournals.com - Health Care News
Onconetix (ONCO) and Ocuvex Consider Strategic Merger
4/8/2025 - GuruFocus
Why Onconetix (ONCO) Stock Is Exploding Higher
4/8/2025 - Benzinga
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
4/8/2025 - GuruFocus
Onconetix signs non-binding LOI for potential combination with Ocuvex
4/8/2025 - TipRanks Financial Blog
Onconetix signs non-binding LOI for potential combination with Ocuvex
4/8/2025 - The Fly
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
4/8/2025 - Globe Newswire
Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader
4/4/2025 - BizJournals.com - Nat'l Business News
Onconetix Appoints Karina Fedasz as Interim CEO
4/3/2025 - TipRanks Financial Blog
Short Interest in Onconetix, Inc. (NASDAQ:ONCO) Grows By 252.7%
3/29/2025 - Ticker Report
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test ...
3/24/2025 - GuruFocus
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort
3/24/2025 - TipRanks Financial Blog
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort
3/24/2025 - The Fly
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
3/24/2025 - Globe Newswire
Onconetix (NASDAQ:ONCO) Trading Up 4.2% - What's Next?
3/22/2025 - Ticker Report
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix ...
3/19/2025 - GuruFocus
Onconetix announces new clinical data for Proclarix to be presented at EAU
3/19/2025 - The Fly
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
3/19/2025 - Globe Newswire
Onconetix taps industry veteran as executive chairman amid CEO resignation
3/3/2025 - Bizjournals.com - Health Care News
Onconetix Announces Leadership Changes and New Appointments
2/28/2025 - TipRanks Financial Blog
Onconetix, Inc. (NASDAQ:ONCO) Sees Significant Decline in Short Interest
2/28/2025 - Ticker Report
Zurcher Kantonalbank Reduces Stake in Onconetix Inc
2/7/2025 - GuruFocus
Onconetix files to sell 50M shares of common stock for holders
1/27/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$1.87M
EBITDA (TTM)
-$13.10M
EBIT (TTM)
-$13.75M
Net Income (TTM)
-$51.60M
Balance Sheet
Total Assets (Q)
$61.92M
Total Debt (Q)
$10.12M
Total Liabilities (Q)
$20.90M
Book Value Per Share (Q)
$4.08
Cash Flow
Cash from Operations (TTM)
-$13.89M
Cash from Investing (TTM)
$1.19M
Cash from Financing (TTM)
$5.44M
Net Change in Cash (TTM)
-$7.31M
Filings
Filing Date
Tuesday, December 10, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Apr 7 and 11 (est)
Price History
Loading...
Beta
2.45
7-Day Total Return
27.90%
30-Day Total Return
-39.60%
60-Day Total Return
-86.02%
90-Day Total Return
-81.88%
Year to Date Total Return
-88.31%
1-Year Total Return
-98.36%
2-Year Total Return
-99.82%
3-Year Total Return
-99.95%
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $0.0502
52-week High
May 29, 2024 - $21.40
Valuation
Market Cap
$663.58K - Nano Cap
Enterprise Value
$17.55M
Price/Sales (TTM)
0.06
Price/Book (Q)
0.02
Dividends and Shares
Shares Outstanding
1.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
onconetix.gcs-web.com
Phone Number
513 620 4101
Address
201 East Fifth Street
Cincinnati, OH 45202
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed